Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment Academic Article uri icon

Overview

MeSH Major

  • Anilides
  • Antineoplastic Agents
  • Liver Diseases
  • Neoplasms
  • Pyridines

abstract

  • Hepatic impairment does not appear to impact vismodegib PK, and therefore, dose adjustment is not necessary in this special population. The study was influenced by the high number of patients with hepatocellular carcinoma with advanced cirrhosis; rendering it difficult to draw any causal relationships between vismodegib exposure and the serious adverse events.

publication date

  • July 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5520972

Digital Object Identifier (DOI)

  • 10.1007/s00280-017-3315-8

PubMed ID

  • 28523596

Additional Document Info

start page

  • 29

end page

  • 36

volume

  • 80

number

  • 1